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Introduction. In selected patients, the absorbable fibrin patch TachoSil® is superior to standard surgical treatment in reducing air
leakage after pulmonary lobectomy. Pulmonary involvement is not considered a main feature of Marfan syndrome (MFS);
however, spontaneous pneumothorax (SP) with a high rate of recurrence is frequently reported. We describe the use of
TachoSil® in the supportive treatment of recurrent pneumothorax in a girl with MFS. Case Report. A 12-year-old girl with a
previous diagnosis of MFS and recurrent history of left spontaneous pneumothorax was submitted to thoracoscopic atypical
lung resection. Two patches (9.5× 4.8 cm) were cut from the adhesive/foam complex (TachoSil®) and were pressed against the
sutured area as supportive treatment. The patient recovered with no further SP recurrences. Conclusions. The use of the
TachoSil® surgical patch may be useful in pneumothorax supportive treatment, particularly in pediatric MFS by ameliorating
the mechanical strength of the lung.
1. Introduction
Marfan syndrome (MFS) is a connective tissue disorder com-
prising multiple organ manifestations caused by a mutation
in the gene FBN1 that codes for the protein, fibrillin-1 [1].
Although pulmonary symptoms are not generally considered
a main feature of Marfan syndrome, many patients have a
degree of underlying pulmonary pathology, such as cystic
changes, emphysema, spontaneous pneumothorax (SP),
focal pneumonia, bronchiectasis, bullae, congenital pulmo-
nary malformations, and apical fibrosis [2, 3]. SP is the most
frequent respiratory manifestation in MFS, with an associ-
ated prevalence that is between 5 and 11% [3–5]. The optimal
SP treatment inMFS remains unclear because of the high rate
of recurrence.
TachoSil® is a sterile ready-to-use absorbable patch for
intraoperative topical application. In selected patients,
TachoSil® is more effective than standard treatment of air
leakage after pulmonary lobectomy [6]. Limited data on
TachoSil® use in thoracic surgery in the pediatric age are
available [7]; thus, we investigated the use of TachoSil® in
supportive treatment for recurrent pneumothorax in a girl
with MFS.
2. Case Report
A 12-year-old girl with a previous diagnosis of MFS was
admitted in our Pediatric Surgery Unit with sudden onset
of chest pain and shortness of breath after sneezing. Her past
medical history revealed two previous left spontaneous
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pneumothorax (two and three months prior to this hospi-
tal admission), managed with conservative measures and
pleural drainage.
Upon examination, both physical and radiographic find-
ings were compatible with a pneumothorax recurrence on
the left side. A thoracic CT scan showed bullous pulmonary
dysplasia (Figure 1). Thoracoscopic treatment included
resection of the pneumopleural adhesions and bullae. The
procedure was performed with the patient in a lateral decubi-
tus position. Three valved ports, ranging in size from 3 to
5mm, were used. The first port was placed in the mid to
the anterior axillary line in the fifth interspace to determine
the position of the major fissure and evaluate the lung
parenchyma. The position of the fissure dictates the place-
ment of the other ports. The working ports were placed
in the anterior axillary line above and below the camera port.
Lung resection, including the parenchymal area involved in
the lesion, was performed using the LigaSure® device. A lung
specimen was removed using a protective specimen endo-
bag through a 5mm port. No postsurgical drainage tubes
were positioned. The patient was discharged on the eighth
postoperative day.
One week later, a pneumothorax recurrence necessitated
a second thoracoscopic intervention. Further pulmonary
resection of the atypical upper left lobe was performed using
a stapling device. Two patches (9.5× 4.8 cm) were cut from
the adhesive/foam complex (TachoSil®), rolled and inserted
into the 5mm trocar, and subsequently stretched over the
sutures. No drainage tubes were inserted. The postoperative
period was uneventful, and the patient was discharged one
week later. Gross findings showed severe emphysematous
involvement in the upper lobe with marked bulla formation
(Figure 2(a)). Microscopic examination revealed a character-
istic emphysema morphological pattern juxtaposed to nor-
mal lung parenchyma (Figure 3(a)).
Three months later the patient was admitted again, this
time with a right-sided pneumothorax. A thoracoscopic
intervention on the atypical section of the upper right lobe
was performed using a stapling device (Figure 2(b)), and
new pieces of the TachoSil patch were applied. No thoracic
(a) (b)
(c)
Figure 1: Lung imaging. (a) Chest X-ray. A total collapse of the left lung was showed. (b, c) Thoracic CT. A bullous pulmonary dysplasia was
noted (the bullous lesion is indicated with an arrow).
2 Case Reports in Surgery
(a) (b)
Figure 2: Gross findings of the upper lobe at first (a) and second (b) surgical interventions. Emphysematous changes with marked bulla
formation were present.
(a)
(b)
(c)
Figure 3: Pulmonary specimen evaluation, after first (a) and second (b, c) surgical interventions; all specimens showed distal acinar
emphysema.
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drainage tubes were inserted. Microscopic findings shown in
Figures 3(b) and 3(c) evidenced emphysematous changes. At
six-month follow-up, the patient was in good condition with
no further pneumothorax recurrences.
3. Discussion
MFS is a rare genetic connective tissue disorder with skeletal,
ocular, and cardiovascular manifestations [1]. Pulmonary
involvement occurs infrequently, with SP being the most
commonly reported. However, MFS patients have a PS risk
that is 10 times higher than that of the general population
[3–5]. The causal gene for MFS, FBN1, encodes for extra-
cellular matrix glycoprotein fibrillin-1, which is found in
the lung and is a component of elastic fibres. Abnormalities
in fibrillin result in connective tissue friability and laxity
[1]. These features, within the lung, can result in flaccidity
of small airways and terminal bronchioles, predisposing to
premature airway closure, obstruction, and air trapping
leading to degenerative changes and emphysema, which
may be the main mechanism for pneumothorax in these
individuals [8]. Increased mechanical stress in the lung api-
ces of the characteristically tall MFS body habitus is also a
consideration [8].
Specific histological changes in a Marfan lung have not
been completely characterized in microscopic detail; how-
ever, it is commonly accepted that in MFS, the gross patho-
logical condition of the lung corresponds with “fragile lung”
at microscopic evaluation [9]. Emphysematous changes have
been described in terms of geographic location (e.g., upper vs.
lower lobe, bilateral vs. unilateral). In our case, the distal
acinar emphysema represents a histologic pattern which
correlates with MFS [10] and an underlying history of SP.
Dyhdalo and Farver [10] have reported that these changes
occur just beneath the pleural surface, while sparing the sur-
rounding acini. Areas of scarring may be present in the distal
septa, although with significant separation from other areas
of more typical emphysematous changes. Some cases have
shown discrete foci of emphysematous changes, while others
display more extensive alveolar destruction.
It is however essential to remember that distal acinar
emphysema is not a distinguishing feature of MFS and may
be seen in other disease processes, notably in tall, thin males
with SP. It is important to interpret pathological findings in
the context of clinical history and imaging studies.
The relationship between upper lobe pulmonary fibrosis
and MFS has also been reported in MFS [11]. Thus, it is
tempting to speculate that the fibrosis might be the result of
prior scarring caused by stress in the apical sections of the
lungs of these tall people, the site where mechanical damage
would be expected to be maximal [11].
Therapeutic options for SP include bed rest, oxygen sup-
plementation, manual aspiration, chest tube drainage, and
thoracoscopic and surgical interventions [12]. There is a lack
of consensus between different international guidelines
regarding many aspects of pneumothorax management in
the pediatric age. In patients with MFS, treatment should
be more aggressive and definitive surgical treatment should
be performed at the first occurrence of pneumothorax
because of the high rate of recurrence after chest tube treat-
ment. Open surgery and thoracic drainage are not recom-
mended to decrease the risk of the pneumopleural adhesion
formation. Thoracoscopic surgery, as a minimally invasive
approach, should be considered the treatment of choice.
Considering the tissue fragility, stapling devices should min-
imize trauma and support the suture to prevent air leakage.
The TachoSil® surgical patch also favours blood clotting, cre-
ates sealing barriers, and facilitates the bonding of tissue
components, including pulmonary tissue.
TachoSil® is a sterile ready-to-use absorbable patch for
intraoperative topical application. It consists of an equine
collagen patch coated with fibrin glue components: human
fibrinogen and human thrombin. It thus combines the
benefits of a pliable material with the hemostatic and
adhesive properties of coagulation factors. The product is
currently approved in Europe for supportive hemostatic
surgical treatment where standard techniques are insuffi-
cient. The efficacy and safety of TachoSil® have been dem-
onstrated in adults following digestive and hepatobiliary
surgery (liver resection), in pulmonary lobectomy, in seal-
ing the percutaneous nephrolithotomy tract, kidney resec-
tion, open repair of abdominal aortic aneurysm, during
splenectomy for oncohemathological conditions, after dis-
tal pancreatectomy, for obstetric and gynecologic surgery,
inguinofemoral and axillary lymphadenectomy, and in a
case of corneal perforation [13–21].
There are few studies which have evaluated the use of
TachoSil in pediatric surgery. Vida et al. [22] and Gior-
dano et al. [23] described TachoSil use in children with
congenital heart disease who underwent heart surgery in
order to control bleeding. Mele et al. [24] reported a pre-
liminary pediatric experience using this hemostatic agent
during nephron sparing surgery. Mirza et al. [25] and
Lacanna et al. illustrated the use of TachoSil for hemosta-
sis in children undergoing liver transplantation. Molnar
et al. [7] described a parenchyma sparing method using
a sealant-hemostatic complex foam in a boy suffering from
cystic fibrosis of the lung and in a girl with bronchopneu-
monia in artificial ventilation for acute respiratory distress
syndrome and sepsis.
There are no reports in the literature on TachoSil use in
pediatric thoracic surgery in MFS. We hypothesized that
additional sealing of the anastomosis with a fibrin patch, con-
taining human fibrinogen and thrombin, would improve pul-
monary mechanical strength. TachoSil® may be considered
effective support in surgical treatment to prevent SP recur-
rence in children and adolescents with MFS.
4. Conclusion
In MFS patients, definitive surgical treatment should be per-
formed at the first occurrence of pneumothorax because of
the high rate of recurrence. The use of the TachoSil® surgical
patch should be useful in pneumothorax supportive treat-
ment in MFS in order to ameliorate the mechanical strength
of the lung, limit the use of postsurgical drainage tubes, and
prevent PS recurrence in the pediatric age.
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